Pacific Edge to launch eCommerce site for diagnostic testing
Dunedin-based cancer diagnostics company Pacific Edge will launch an eCommerce platform this month to allow consumers to order a urine test for bladder cancer online, with the results sent to their GP.
Pacific Edge, which makes a non-invasive diagnostic system called Cxbladder that measures the gene expression levels of five biomarker genes that represent a bladder cancer signature, distributes the product through its Pacific Edge Diagnostics arms in New Zealand and the US, and through Healthscope Advanced Pathology in Australia.
Cxbladder is a urine-based detection test for bladder and other urinary tract cancers that only requires a small volume of sample. Patients presenting with blood in the urine will be able to order a test online and will be sent a urine sampling system (USS) developed by Pacific Edge. They can then collect a sample in their own home, without the need to visit their doctor or specialist.
The sample is tested at the company's laboratory in Dunedin and within seven days, a detailed test report is sent to their nominated GP. The test also helps doctors to identify if a patient has a high probability of bladder cancer and is a complement to cytoscopy. It can also be used to monitor cancer recurrence.
The eCommerce site has been reviewed and approved by the New Zealand Medicines and Medical Devices Safety Authority, and the therapeutic advertising pre-vetting system of the Advertising Standards Authority.
Pacific Edge, which earlier this year won a grant of up to $NZ4.5 million over three years from Callaghan Innovation, is developing a range of cancer detection tests using genomic and proteomic tools.
Posted in New Zealand eHealth